A Phase IV Multicenter Trial to Evaluate the Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib and Its Companion Diagnostic Test in Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC) Patients
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 05 Jun 2018 Results assessing molecular predictors to determine the rate and duration of response presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 29 Aug 2017 Planned End Date changed from 1 Jul 2017 to 1 Jun 2018.
- 29 Aug 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Mar 2018.